Trials / Completed
CompletedNCT04089267
Evaluating the Efficacy and Safety of Different Human Thrombopoietin (rhTPO) Regimens in the Treatment of Patients With Primary Immune Thrombocytopenia (ITP)
Multicenter, Randomized, Open, Parallel Controlled Trials Evaluating the Efficacy and Safety of Different Human Thrombopoietin (rhTPO) Regimens in the Treatment of Patients With Primary Immune Thrombocytopenia (ITP)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 288 (actual)
- Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a review of the efficacy and safety of different recombinant human thrombopoietin (rhTPO) regimens in the treatment of patients with primary immune thrombocytopenia (ITP).
Detailed description
Evaluating the efficacy and safety of different human thrombopoietin (rhTPO) regimens in the treatment of patients with primary immune thrombocytopenia (ITP) This trial was designed as a multicenter, randomized, open, parallel controlled study
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TPO |
Timeline
- Start date
- 2016-12-01
- Primary completion
- 2018-12-01
- Completion
- 2019-08-01
- First posted
- 2019-09-13
- Last updated
- 2019-09-13
Locations
21 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04089267. Inclusion in this directory is not an endorsement.